US Regulatory Reads, August 2017: MDUFA IV; Risk-Benefit; Gastric-Balloon Warning
Executive Summary
The biggest US medtech policy news in August was enactment of the law reauthorizing medical-device user fees and making other US FDA reforms. But also attracting significant interest in Medtech Insight last month was our expert compliance tips, a deep-dive into FDA's new risk-benefit framework for making enforcement decisions and a safety alert from the agency tied to recently approved gastric balloons for obesity.
You may also be interested in...
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?
Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.